• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sinobiopharma Secures Rights to Seven Key Patents

Posted on: Monday, 27 April 2009, 15:37 CDT

NANJING, China, April 27 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has secured rights to seven key patents from Company CEO Dr. Lequn Huang and the patents' co-holders. The patents that will significantly enhance Sinobiopharma's ability to execute on its mission of bringing safe, low-cost, high-efficacy biopharmaceuticals to market.

The patents are for the following:

1. Synthesis of amantadine hydrochloride
2. Method for preparation of 17-acylsinomenine derivatives
3. Preparation of 17-sulfonylsinomenine
4. Preparation of N-substituted sinomenine
5. Method for preparation of Sinomenine compound having dextro-rotary C ring-deficient morphinan skeleton
6. Synthesis of Eplerenone from 11 -hydroxycanrenone
7. Method for resolving tetrahydroisoquinoline racemate

Sinobiopharma will be applying these patents as well as using its own innovative applications of them in new drug development.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

SOURCE Sinobiopharma, Inc.

Source: PR Newswire

More News in this Category